Mayne Pharma Group – ProThinker – Analytics for Informed Decisions

Stock Valuation: Mayne Pharma Group Ltd (MYX)

Name of Company Country of Origin/ Exchange Traded Sector Stock Price MAYNE PHARMA GROUP LTD Australia/ ASX Healthcare – Drug Manufacturers – Drug Manufacturers – Major AUD1.18 @ 31 Aug 2018 COMPANY PROFILE Mayne Pharma Group Ltd is a specialty pharmaceutical company. It develops, manufactures and markets branded and generic products. It has two drug … Continue reading

The same valuation methodology we use for markets is also used for stocks. All combinations of the five valuation indicators are tested and the best combinations selected to forecast the stock price in one year’s time.

Target price determination is 100% objective and serves as a good independent check to forecasts by analysts.
Available for thousands of stocks that you cannot find analyst reports for. Stocks that are less well researched have more mispricing opportunities and potential to generate alpha.
Stock reports do not just cover valuation; there are over 30 pages of analysis on all aspects of the stock – valuation, earnings, financial condition, cash flow, quality of earnings, operational efficiency, dividends, analyst opinions, comparison with market, sector and industry, technical indicators, etc.